These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20808209)

  • 1. Pros and cons of composite endpoints in anesthesia trials.
    Myles PS; Devereaux PJ
    Anesthesiology; 2010 Oct; 113(4):776-8. PubMed ID: 20808209
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 3. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 5. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 6. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 7. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 9. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some issues with composite endpoints in clinical trials.
    Chi GY
    Fundam Clin Pharmacol; 2005 Dec; 19(6):609-19. PubMed ID: 16313272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
    Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
    Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple-arm superiority and non-inferiority designs with various endpoints.
    Chang M
    Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Liberal' vs. 'restrictive' perioperative fluid therapy--a critical assessment of the evidence.
    Bundgaard-Nielsen M; Secher NH; Kehlet H
    Acta Anaesthesiol Scand; 2009 Aug; 53(7):843-51. PubMed ID: 19519723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How can we improve clinical trials?
    Kaplan RS
    Nat Clin Pract Oncol; 2007 Apr; 4(4):206-7. PubMed ID: 17392712
    [No Abstract]   [Full Text] [Related]  

  • 16. Key issues in end point selection for heart failure trials: composite end points.
    Neaton JD; Gray G; Zuckerman BD; Konstam MA
    J Card Fail; 2005 Oct; 11(8):567-75. PubMed ID: 16230258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical methods in clinical trials.
    Gebski VJ; Keech AC
    Med J Aust; 2003 Feb; 178(4):182-4. PubMed ID: 12580749
    [No Abstract]   [Full Text] [Related]  

  • 18. A combined score test for binary and ordinal endpoints from clinical trials.
    Whitehead J; Branson M; Todd S
    Stat Med; 2010 Feb; 29(5):521-32. PubMed ID: 20082364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 20. Statistical grand rounds: design and analysis of studies with binary- event composite endpoints: guidelines for anesthesia research.
    Mascha EJ; Sessler DI
    Anesth Analg; 2011 Jun; 112(6):1461-71. PubMed ID: 21543784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.